Search
Oral Presentation
A randomized, double-blind, phase III study comparing trifluridine/tipiracil versus placebo in patients with molecular residual disease following curative resection of colorectal cancer: The ALTAIR study
Bando H, Watanabe J, Kotaka M, et al.
Poster Presentation
Real-world clinical outcomes of metastatic colorectal cancer (mCRC) patients Who received Trifluridine-Tipiracil (FTD-TPI) monotherapy or FTD-TPI + Bevacizumab (FTD-TPI+bev) combination therapy
Nusrat M, Zhao R, Khan N, et al.
Poster Presentation
Real-world clinical outcomes of Trifluridine-Tipiracil monotherapy (FTD-TPI) and FTD-TPI + Bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients with metastatic colorectal cancer (mCRC)
Nusrat M, Zhao R, Khan N, et al.
Poster Presentation
Phase 1b study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Evaluating the immunological effects
Kojima T, Shinohara H, Eguchi S, et al.
Poster Presentation
Zimberelimab platform study: Safety and efficacy of zimberelimab in combination with futibatinib and chemotherapy in patients with first-line advanced or metastatic esophageal carcinoma
Fukuoka S, Machida N, Mitani S, et al.
Poster Presentation
A randomized, double-blind, phase III study comparing trifluridine/tipiracil versus placebo in patients with molecular residual disease following curative resection of colorectal cancer: The ALTAIR study
Bando H, Watanabe J, Kotaka M, et al.